|
||||||||||||||||||||||
![]() |
|
|
|
![]() |
Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment
Basic Trial Information
Summary Study to investigate an anticancer cellular immunotherapeutic, AGS-003, when used in combination with sunitinib in subjects with previously untreated advanced stage RCC. Further Study Information The purpose of this study is to investigate an anticancer immunotherapeutic, AGS-003, when used in combination with sunitinib (the treatment regimen) in a single-stage, Phase II design in subjects with previously untreated advanced stage RCC after nephrectomy/excisional biopsy/metastasectomy. AGS-003 is formulated using mature DCs co-electroporated with CD40L IVT RNA and autologous total tumor RNA Eligibility Criteria Inclusion Criteria: Male and female subjects ≥18 years of age with newly diagnosed advanced stage RCC will be eligible for inclusion in this study if all of the following criteria apply: 1. Newly diagnosed advanced stage RCC. 2. Eligible for unilateral nephrectomy or partial nephrectomy; OR, Has lesion accessible for excisional biopsy/metastasectomy. 3. Measurable disease. 4. Candidate for sunitinib treatment as labeled. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 6. Memorial Sloan Kettering Cancer Center (MSKCC) risk group 0 or 1. 7. No brain metastases detected by MRI. 8. Normal renal function in the contralateral kidney. 9. Able to abstain from taking prohibited prescription or prohibited non-prescription drugs. 10. Use of appropriate birth control methods for the duration of the study for women of childbearing potential and men with female partners of childbearing potential. 11. Clinically acceptable Screening results according to the following specific limits:
12. Normal serum calcium. 13. Ability to communicate effectively with study personnel; considered reliable, willing, and cooperative in terms of compliance with the Protocol requirements. 14. Voluntary informed consent given to participate in the study. Exclusion Criteria: Subjects will NOT be eligible for inclusion in this study if any of the following criteria apply: 1. Nephrectomy for RCC therapy is required. 2. Any serious medical condition or illness considered by the investigator to constitute an unwarranted high risk for investigational treatment. 3. Uncontrolled hypertension. 4. Type I diabetes mellitus (insulin therapy for Type II diabetes IS permitted). 5. Prior systemic therapy for advanced stage RCC. 6. Active autoimmune disease. 7. Prior history of malignancy other than RCC within the preceding 5 years, except for adequately treated cervical cancer or non-melanoma skin cancer. 8. Use of prohibited prescription or prohibited non-prescription drugs during 2 months prior to entry into the study. 9. Active, acute, or chronic clinically significant infections. 10. Use of another investigational drug or participation in any investigational drug study within the 28 days prior to the start of study enrollment. 11. Planned or elective anti-cancer surgical treatment other than nephrectomy/excisional biopsy/metastasectomy. 12. History of hypercalcemia, symptomatic hypercalcemia, or hypercalcemia requiring management. 13. Known hypersensitivity to dimethyl sulfoxide (DMSO). 14. Body weight less than 30 kg. 15. Pregnancy or lactation. Trial Lead Organizations/Sponsors Argos Therapeutics, Incorporated
Trial Sites
Link to the current ClinicalTrials.gov record. Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov. Back to Top |
![]() |
![]() |
![]() |
![]() |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
![]() A Service of the National Cancer Institute |
![]() |
![]() |